Analytical Data
-
基因名
FcgR3B
- Application
-
别名
CD16b; CD16-B; FCGR3-B; FCG3; FcgRIII; Low affinity immunoglobulin gamma Fc region receptor III-B
-
种属
Human
-
表达系统
HEK293
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75015
-
表达区间
Pro24~Ser203
-
分子量
38-44kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FcgR3B, also known as CD16b, is an essential receptor belonging to the Fc gamma receptor family, which plays a crucial role in the immune system by mediating the interaction between antibodies and immune effector cells. This receptor is primarily expressed on neutrophils and is involved in processes such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, making it vital for the immune response against infections and tumors. Recent studies have highlighted the importance of FcgR3B in various diseases, including autoimmune disorders and cancer, where its expression and functionality can significantly impact disease progression and treatment efficacy. The development of recombinant FcgR3B proteins has garnered attention for their potential use in therapeutic applications, including monoclonal antibody therapies, where enhancing ADCC could improve the targeting and destruction of malignant cells. Moreover, recombinant FcgR3B could serve as valuable tools in research to better understand receptor-ligand interactions and the dynamics of immune responses. Understanding the structure and function of FcgR3B, combined with advancements in recombinant protein technology, opens new avenues for innovative therapeutic strategies that exploit the immune system's capability to combat diseases. Thus, the ongoing research on FcgR3B recombinant proteins aims to elucidate their biological roles, optimize therapeutic applications, and potentially lead to the development of more effective treatments for various health conditions.
